Cannabidiol in dentistry: a scoping review

The CBD has many reports of pharmacological effects in various models of pathologies, ranging from inflammatory and neurodegenerative diseases, epilepsy, autoimmune disorders such as multiple sclerosis, arthritis, schizophrenia among others (1). In other medical areas has been developing CBD as great therapeutic possibilities, with much research in pre-clinical phases (laboratory tests), reviews about complex diseases of the oral cavity (2) and expression of endocannabinoids receptors in the dental and periodontal tissues (3,4).
However, the use of CBD in the dental field has been poorly studied and limited, and its effects in the treatment of oral diseases are not well known and reported. Similarly, knowing its properties, mechanisms of action and favorable results in the treatment of other oral diseases, it is believed that it may have a positive therapeutic effect in some pathologies of CBD therapeutic dentistry based on scientific publications that discuss its mechanism of treatment action, suggesting possibilities for future investigations on the use of this compound in dentistry in previous years. Therefore, the purpose of this scoping review will be to map the available evidence to provide an overview and technology of the use of cannabidiol, its effects, and related products in dentistry.

References.
1.PISANTI, Simona, et al. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacology & therapeutics, vol. 175, p. 133-150, 2017. DOI: https://doi.org/10.1016/j.pharmthera.2017.02.041.
2.CUBA, L. F., et al. Cannabidiol: an alternative therapeutic agent for oral mucositis?. Journal of clinical pharmacy and therapeutics, 2017, vol. 42, no 3, p. 245-250.
3. Abidi, Ammaar H., et al. "Anti-inflammatory activity of cannabinoid receptor 2 ligands in primary hPDL fibroblasts." Archives of oral biology 87 (2018): 79-85.
4.KONERMANN, Anna, et al. In vivo and in vitro identification of endocannabinoid signaling in periodontal tissues and their potential role in local pathophysiology. Cellular and molecular neurobiology, 2017, vol. 37, no 8, p. 1511-1520.

在大脑病理性模型中，例如炎症性疾病、神经退行性疾病、癫痫、多发性硬化症、关节炎和分裂症等自身免疫性疾病，已有多项报告显示CBD（大麻二酚）具有药理作用（1）。在其他医学领域，CBD作为卓越的治疗可能性正在被开发，其在临床试验阶段（实验室测试）的研究、关于口腔复杂疾病的综述（2）以及牙体和牙周组织中内源性大麻素受体的表达（3,4）等方面均有涉及。然而，CBD在牙科领域的应用研究尚显不足且有限，其在治疗口腔疾病中的效果尚不明确。同样，鉴于其对其他口腔疾病的特性、作用机制及有益的治疗结果，有理由相信它可能在基于科学文献讨论其治疗作用机制的CBD牙科病理学中产生积极的疗效。因此，本次范围综述的目的是梳理现有证据，以概述和阐述大麻二酚及其相关产品在牙科领域的应用、作用及其相关技术。

参考文献。
1.PISANTI, Simona, 等人. 大麻二酚：现状与治疗应用的新挑战. 药理学与治疗学，第175卷，第133-150页，2017. DOI: https://doi.org/10.1016/j.pharmthera.2017.02.041.
2.CUBA, L. F., 等人. 大麻二酚：口腔黏膜炎的替代治疗剂?. 临床药学与治疗学杂志，2017年，第42卷第3期，第245-250页。
3.Abidi, Ammaar H., 等人. "Cannabinoid受体2配体在原代人牙周膜成纤维细胞中的抗炎活性." 口腔生物学档案，第87卷，2018年，第79-85页。
4.KONERMANN, Anna, 等人. 在体和离体识别牙周组织中内源性大麻素信号传导及其在局部病理生理学中的潜在作用. 细胞与分子神经生物学，2017年，第37卷第8期，第1511-1520页。